论文部分内容阅读
过去两年综合过会率最低的医药行业的IPO情况,在2017年上半年并没有得到明显改善。据统计,2017年上半年A股市场共有247家上市公司首发上市,其中有18家医药企业,占上半年首发上市247家企业的7.29%。在上市新政与审核进度加快的背景下,今年以来每天2只、每周10只左右新股发行已是常态,与2016年同期两市仅有61家公司首发上市,上市数量同比激增304.92%相比,医药企业今年上市的速度显然是差强人意,与医药产业在
In the first half of 2017, the IPO situation of the pharmaceutical industry with the lowest overall cross-over rate in the past two years did not show any significant improvement. According to statistics, a total of 247 listed companies were listed on the A-share market in the first half of 2017, of which 18 were pharmaceutical companies, accounting for 7.29% of the 247 companies listed in the first half of the year. Against the backdrop of the new Deal and the progress of the audit, two new units and 10 new stock issuances per week have been the norm since the beginning of this year. Compared with the initial public offering of only 61 companies in the same period of 2016, the number of listed companies surged by 304.92% on a year-on-year basis , The speed of listing of pharmaceutical companies this year is clearly unsatisfactory, and the pharmaceutical industry